Dissolution Rate Enhancement, Design and Development of Buccal Drug Delivery of Darifenacin Hydroxypropyl <i>β</i>-Cyclodextrin Inclusion Complexes

<table><i>In vitro</i> release profile of different formulations of HPMC K100 M CR containing Hp<i>β</i>-CD-darifenacin complex. Hb1–Hb5 formulations of HPMC K100 M CR containaing 1%–5% of the polymer, D-formulation containing pure drug.</table>

Journal of Pharmaceutics

fig6

Figure 6

Figure 6: Dissolution Rate Enhancement, Design and Development of Buccal Drug Delivery of Darifenacin Hydroxypropyl <i>β</i>-Cyclodextrin Inclusion Complexes 

Figure 6 | Dissolution Rate Enhancement, Design and Development of Buccal Drug Delivery of Darifenacin Hydroxypropyl β-Cyclodextrin Inclusion Complexes 